KLP Kapitalforvaltning AS Invests $1.56 Million in Repligen Co. (NASDAQ:RGEN)

KLP Kapitalforvaltning AS acquired a new position in Repligen Co. (NASDAQ:RGEN) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 10,800 shares of the biotechnology company’s stock, valued at approximately $1,555,000.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC lifted its position in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the third quarter valued at about $37,000. Quarry LP raised its holdings in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. boosted its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC grew its stake in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 129 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent analyst reports. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Repligen has a consensus rating of “Hold” and an average target price of $178.64.

Repligen Stock Down 2.7 %

RGEN opened at $133.41 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a fifty day moving average of $154.21 and a 200-day moving average of $148.14. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $184.98. The company has a market capitalization of $7.49 billion, a P/E ratio of -261.59, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. On average, equities analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Insiders Place Their Bets

In related news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.